Masakazu Toi (Kyoto University Hospital, Kyoto, Japan) presented the results of the randomised, phase 3 POTENT trial. 1959 patients with hormone receptor-positive, HER2-negative, stage I–III primary breast cancer at intermediate or high risk of recurrence were randomly assigned (1:1) after surgery to standard adjuvant endocrine therapy alone (control) or with oral S-1 (80 mg, 100 mg, or 120 mg…
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended…
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended…
The benefit-risk assessment of cancer treatments usually focuses on traditional clinical and disease outcomes, such as overall survival, progression-free survival, and tumour response, balanced against…
Talazoparib plus enzalutamide prolonged time to definitive deterioration in GHS/QoL versus placebo plus enzalutamide. Together with clinical efficacy and safety data, these results inform the…
The demonstrated delays in definitive deterioration in GHS/QoL, urinary symptoms, and other functioning and symptom scales with talazoparib plus enzalutamide compared with placebo plus enzalutamide…
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended…
With more than 7 years of follow-up, D-VMP continued to elicit clinical benefits in transplant-ineligible patients with newly diagnosed multiple myeloma, supporting the efficacy and…
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended…
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended…
Belzutifan for advanced renal cell carcinoma was associated with improved disease-specific symptoms and QOL compared with everolimus. Taken together with the efficacy and safety data…
